Key Segments
By Application
-
Plaque Psoriasis
-
Psoriatic Arthritis (PsA)
-
Others
By Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
-
Mexico
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Turkey
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Singapore
-
Australia
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g., Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Tremfya is well-positioned as a first-in-class IL-23 inhibitor with subcutaneous and IV dosing flexibility, making it a preferred choice for long-term disease control.
Major competitors include AbbVie (Skyrizi), Eli Lilly (Taltz), Novartis (Cosentyx), Amgen, and UCB, which offer similar biologics in the IL-23, IL-17, and TNF spaces.
North America dominates the Tremfya market with over 85% share in 2024, followed by Europe, due to early approvals, high diagnosis rates, and broad insurance coverage.
Key growth drivers include rising prevalence of autoimmune conditions, increasing demand for IL-23 inhibitors, favorable clinical outcomes, and strong regulatory support for label expansion.
Over the past five years, the Tremfya market has grown steadily due to expanded indications, wider geographic access, and its strong safety-efficacy profile compared to older biologics.
Get in Touch
